Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin FlexPro, is a recombinant human growth hormone presented as a solution for injection (pre‑filled pen) for subcutaneous use. It is indicated for treating growth hormone deficiency and related growth disorders in children and adults.

GNH USA supplies Norditropin FlexPro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global demand. Customers benefit from reliable cold‑chain logistics and comprehensive technical support.

Norditropin FlexPro, a recombinant human growth hormone, is used to address conditions characterized by growth hormone deficiency or impaired growth.

Growth hormone deficiency in children: promotes linear growth and improves IGF‑1 levels. Turner syndrome: enhances stature and supports normal pubertal development. Prader‑Willi syndrome: aids in increasing height and improving body composition. Chronic renal insufficiency: helps counteract growth retardation associated with renal disease. Short stature associated with small for gestational age: stimulates growth velocity toward normal ranges. Adult growth hormone deficiency: improves body composition, bone density, and quality of life.

Somatropin therapy may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema. - Headache. - Peripheral edema. - Arthralgia. - Hyperglycemia. - Fatigue.

Serious or Rare Side Effects: - Intracranial hypertension. - Slipped capital femoral epiphysis. - Severe allergic reactions (anaphylaxis). - Pancreatitis. - Tumor progression in patients with active malignancy.

When prescribing Norditropin FlexPro, clinicians should observe several safety considerations to optimize benefit and reduce risk.

Dose individualization: adjust based on IGF‑1 levels, growth response, and clinical monitoring. Glucose monitoring: assess blood sugar as therapy can induce hyperglycemia. Tumor surveillance: evaluate for existing malignancies because GH may promote tumor growth. Intracranial pressure: monitor for signs of increased pressure, especially in children. Thyroid function: check thyroid status as GH can affect hormone balance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Insulin: may require dose adjustment due to hyperglycemic effect of GH. - Glucocorticoids: can antagonize the anabolic actions of GH. - Oral estrogen therapy: reduces IGF‑1 response to GH.

Moderate Interactions (Monitor Closely): - Thyroid hormones: GH may alter thyroid hormone metabolism, requiring monitoring. - Diuretics: may exacerbate fluid retention associated with GH. - Other growth factor therapies (e.g., IGF‑1): additive effects on growth and metabolism.